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Summary A monoclonal antibody recognizing the blood group H type 2 antigen has been obtained from a
BALB/c mouse immunized with MCF-7 (human mammary carcinoma) cells. The specificity of this antibody
(A46-B/BIO, IgM, K) has been identified by haemagglutination tests, immunohistochemistry, binding
inhibition studies, and absorption experiments performed with synthetic oligosaccharides. The antibody is
virtually nonreactive with H type 1 antigen or with closely related type 2 structures (e.g., Y antigen). A46-B/
BiO strongly agglutinates human erythrocytes according to the amount of H substance expressed and can,
therefore, easily discriminate between blood groups Al and A2 as well as A,B and A2B (A1 and A1B are not
or only weakly agglutinated). In immunohistochemistry, this antibody seems to provide a highly specific
reagent for a restricted number of carcinomas and epithelial lineages in tissue sections and in vitro.
Blood group-related carbohydrate antigens are important
parts of membrane glycoproteins and glycolipids. They are
thought to be involved in recognition processes. There is at
present increasing interest in these substances because of
accumulating evidence that they are characteristically modi-
fied during malignant transformation (Hakomori, 1984;
Ginsburg et al., 1984; Feizi, 1985; Uhlenbruck, 1986).
Monoclonal antibodies (mabs) are essential tools for the
analysis of these phenomena. We here describe a new mab
specific for the H type 2 epitope and show its applicability in
blood group serology as well as in immunohistochemistry.
Materials and methods
Generation of hybridoma clone A46-B/BJO
Methodical details were as described in Karsten et al. (1983).
Briefly, BALB/c mice were immunized with live cells of the
human mammary carcinoma cell line MCF-7, derived from a
patient of blood group 0 (Soule et al., 1973). Spleen cells
from one of these mice were fused with X63-Ag8.653 mouse
myeloma cells (Kearney et al., 1979), and supernatants from
hybridomas growing in HAT medium were screened by
means of indirect immunofluorescence tests performed with
MCF-7 and A-204 (human rhabdomyosarcoma, Giard et al.,
1973) cells. Hybridoma A46-B/B10, which produced a mab
reacting with a membrane antigen present on MCF-7 but
absent on A-204 cells, was cloned repeatedly by limiting
dilution on feeder cells, expanded and stored in liquid
nitrogen. Cells of this clone were cultured in RPMI 1640
medium containing 5 x 10-5M 2-mercaptoethanol and 10%
foetal calf or horse serum without antibiotics. (Horse serum,
although well suited for hybridoma growth, disturbs some
tests due to intrinsic anti carbohydrate antibodies). Hybri-
doma cells were checked for mycoplasma contamination by
DNA staining (Chen, 1977) and electron microscopy with
negative results. Ascites fluid was obtained in BALB/c mice
conditioned by pristane and transplanted with 1 to 3 x 106
hybridoma cells. Isotype determination was done by immuno-
diffusion (heavy chain) and dot test (light chain) using
specific antisera (Miles, Slough, UK).
Correspondence: U. Karsten, Zentralinstitut fur Molekularbiologie
der AdW, Robert-Rossle-Str. 10, DDR-1115 Berlin-Buch, GDR.
Received 6 August 1987; and in revised form, 22 March 1988.
Haematological methods
Culture supernatants of A46-B/B1O (titres ranging from 1: 16
to 1:64) were used in standard agglutination tests with
washed erythrocytes resuspended in isotonic NaCI solution
(for details see Pilgrim & Karsten, 1987).
Immunohistochemistry
This was performed with either cell lines grown on multitest
slides (Flow Labs., Bonn, FRG) and analyzed by indirect
immunofluorescence or with cryostat sections cut from
frozen tissue samples (4jm; Frigocut, Reichert, Vienna,
Austria) analyzed by means of a modified peroxidase anti
peroxidase technique (Kupper et al., 1984). Sections were
counterstained with Mayer's haemalum. In some cases alter-
native techniques were employed, e.g. paraffin sections after
formalin or methacarn fixation, or indirect immunoperoxi-
dase staining. Peroxidase and FITC labelled second anti-
bodies were from a commercial source (Staatliches Institut
fur Immunpraparate und Niihrmedien, Berlin, GDR). Mabs
with irrelevant specificity or culture medium alone served as
negative controls.
Inhibition assays
Quantitative analysis of antibody binding to seminal plasma
mucins (4jgml-1) and binding inhibition were performed as
enzyme immunoassays on Immulon plates (Dynatech,
Plochingen, FRG) according to Voller et al. (1976). Anti-
body A46-B/BIO produced as ascites was diluted 1:40 and
mixed with serial two-fold dilutions of saccharides (starting
from 50jigwell) or glycoprotein inhibitors (starting from
100ligwell). Lacto-N-fucopentaose I was purchased from
BioCarb Chemicals, Lund, Sweden, and N-acetyllactosamine
from Sigma, Munich, FRG. Glycoproteins from human
secretions of serologically defined donors were enriched by
hot phenol-saline extraction (Hanisch et al., 1985a), and the
mucins contained in these fractions were separated by exclu-
sion chromatography on Sephacryl S 400 (Hanisch et al.,
1985b). Carbohydrate fractions and neutral saccharide aldi-
tols N4 and N8 with the primary structures Fuca(l-2)
Gal#(1-4)GlcNAc,B(1-3)Galfl(I-3)GaINAc-ol and Fuca(l-2)
Galf (l-4)[Fucae(1-3)]GlcNAc,B (1-3) Gal,B (1-3) GalNAc-ol,
respectively, were isolated from mucins of human seminal
fluid (Hanisch et al., 1985a, 1986). Anti mouse IgG-
phosphatase conjugate and p-nitrophenyl phosphate were
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from Sigma, Munich, FRG. Lectin inhibition was performed
using a cell line expressing the A46-B/B1O antigen, H184A1
(mammary epithelial cells, Smith et al., 1981). Cells were
grown on multitest slides and stained in indirect immuno-
fluorescence after preincubation with Ulex europaeus I lectin
(Serva, Heidelberg, FRG) in serial dilutions (starting from
200pgml-1) at 4°C for h.
Absorption with synthetic oligosaccharides
Synthetic H type I and type 2 oligosaccharides bound to an
inorganic carrier (Synsorb, Chembiomed, Edmonton, Canada)
were washed with PBS, degassed, and incubated with
A46-B/B1O supernatant at room temperature for 16h with
gentle shaking. Antibody titres before and after absorption
were evaluated by haemagglutination with 0 erythrocytes.
The absorption capacity of the Synsorb material had been
estimated in preliminary experiments. Accordingly, 25mg dry
weight of immunosorbent was reacted with lOO,ul super-
natant, titre 1:64. For comparison, an anti H mab commer-
cially available from Chembiomed (Edmonton, Canada) was
included. This mab had an original haemagglutination titre
of 1:16.
Results
The monoclonal antibody A46-B/BIO (IgM, K) first occurred
as an antibody strongly binding to a membrane antigen
present on MCF-7 but absent on A-204 cells (Karsten et al.,
1983). Further examination against a panel of human cell
lines (Table I) revealed the expression of this antigen on 4
out of 5 mammary carcinoma cell lines and on a mammary
epithelial cell line derived from normal breast but trans-
formed in vitro, H184A1. Furthermore, A46-B/BIO stained
all of six carcinoma cell lines, whereas those derived from
mesenchymal tissues (fibroblasts, sarcomas, lymphoid cells)
were completey negative. Thus, at this stage, A46-B/BIO
appeared to detect a carcinoma-associated antigen. Histo-
logical evaluation partly confirmed this conclusion. Carci-
nomas of breast and stomach were in a number of cases at
least focally positive in contrast to their normal epithelial
counterparts (Figure la,c). Among a number of mammary
carcinomas, the expression of the A46-B/B1O antigen
appeared to be blood group dependent (Table II). Moreover,
this antigen was detected on certain normal tissues too, for
instance, in the stratum spinosum and stratum lucidum of
the skin, on acinar epithelial cells of pancreas (Figure lb)
and on epithelial cells of gall bladder and salivary glands.
The reactivity of mab A46-B/B10 with endothelial cells of
blood vessels (Figure lc) and with erythrocytes of certain
individuals again pointed towards a blood group-related
antigen. This could then easily be confirmed by agglutination
experiments with erythrocytes of knwon blood groups, the
results of which are shown in Table III. Briefly, A46-B/BIO
agglutinated strongly erythrocytes of blood groups 0, A2,
and A2B, but not, or only weakly, A1 and AlB. This pattern
of reactivity suggested H antigen specificity. Among blood
group B, both strongly and weakly reactive individuals were
found. The agglutination results could be confirmed by
absorption experiments with packed erythrocytes (not
shown). Embryonal and adult blood samples gave similar
agglutination patterns thus excluding Ii. MN could also be
excluded by respective tests (not shown). Attempts to absorb
A46-B/BIO activity with plasma or saliva from 0 secretors
were negative (data not shown). Because saliva of secretors
contains Leb and Y but not H type 2 antigen (Sakamoto et
al., 1984), this result was compatible with H type 2 specifi-
city of mab A46-B/B10. This suggestion could be confirmed
in further studies employing Ulex lectin and defined sacchar-
ides in binding inhibition experiments. Ulex europaeus I
lectin preferentially binds H type 2 (Pereira et al., 1978). In a
cell line reactive with A46-B/B10 in immunofluorescence,
H184A1 (Table I), binding of this mab, but not that of an






























































'Sources, references, and cultivation conditions see Karsten et al.,
1983,1985. Org8 is one out of a series of normal mammary epithelial
cell lines described in Karsten et al. (1988); bReactiviity indicated as
follows: - =no staining; (+)=weak staining; + =strong staining;
'ALL=acute lymphoblastic leukaemia.
Table II Staining characteristics of mab A46-B/
BlO with cryostat sections of mammary carcinomas
Blood group No. 0 + + + + + +
A 8 8
B 3 3
O 6 2 2 1 1
Total 17 13 2 1 1
Numbers indicate specimens belonging to each
group. Staining intensity is given as follows:
0=negative (no staining); + =less than 10%,
+ + =10 to 90%; + + + =more than 90% of
carcinoma cells stained.
unrelated mab, could be blocked by preincubation with the
lectin in a dose-dependent manner. Pretreatment with 200 or
l00,gml-l completely inhibited staining, whereas lower
doses of the lectin were only partially effective. In a com-
parison of various human secretions, A46-B/B10 bound most
strongly to glycoproteins from seminal fluid. These were
accordingly used in binding inhibition studies. Binding was
most effectively inhibited by gastric mucins from secretors or
by neutral carbohydrates (SPL-N), which had been reduc-
tively cleaved from seminal plasma mucins (Figure 2). The
corresponding sialic acid containing saccharide alditols from
seminal mucins (SPL-A) were much less inhibitory. The
inhibitory activity of neutral carbohydrates was abolished
after chemical cleavage of L-fucose residues with mild acid.
The involvement of L-fucose in the epitope structure recog-
nized by mab A46-B/BIO was further examined with the
following pure, chemically defined H type 2 related sacchar-
ides (Hanisch et al., 1986):
Fuca(]-2)Galfl(l-4)GlcNAc#(1-3)Galfl(l -3)GalNAc-ol
(N4; H type 2 epitope posing), and
Fuca(1-2)Gal,B(1 4)[Fuca(I-3)]GlcNAc,B(11-3)
xGalf3(l-3)GalNAc-ol
(N8; Y epitope posing).
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Figure 1 Examples of cells and tissues expressing the A46-B/B10 antigen (H type 2). Bar=20,um. (a) Cryostat section of
mammary carcinoma. Carcinoma cells focally positive, stromal cells negative; (b) Cryostat section of normal pancreas. Acinar
epithelial cells (exocrine pancreas=ep) positive, islet cells (i) negative; (c) Methacarn fixed paraffin section from normal breast
(reduction mammoplasty, blood group 0). Endothelial cells positive, epithelial and stromal cells negative. (aHc) Peroxidase
technique, counterstained with haemalum. In (c) a strong blue filter was applied in order to reduce the optical dominance of
counterstained nuclei. (d) Cell line Org8 (mammary epithelial cell line derived from a patient blood group A1, undergoing
reduction mammoplasty). Indirect immunofluorescence technique.




strengtha 0 A2 A2B Al A1B B
+ + + + 181b 69 19 3 0 113
(87.4)c (71.9) (41.3) (1.2) (0.0) (26.1)
+ + + 26 23 23 18 0 151
(12.6) (23.9) (50.0) (7.2) (0.0) (34.9)
++ 0 4 4 39 18 102
(0.0) (4.2) (8.7) (15.6) (17.0) (23.6)
+ 0 0 0 89 27 56
(0.0) (0.0) (0.0) (35.6) (25.5) (12.9)
0 0 0 101 61 11
(0.0) (0.0) (0.0) (40.4) (57.5) (2.5)
Totald 207 96 46 250 106 433
aAgglutination strength scored as follows: 0=negative; +=very small agglutinates;
+ + =small but definite agglutinates; + + + =several clots in clear fluid;
+ + + + =clot in clear fluid; bNumbers of samples examined; cPer cent of samples
per blood group reacting according to indicated the agglutination strength; dThese
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Figure 2 Binding inhibition experiments with saccharides
prepared from human seminal mucins. Microtiter plates were
coated with seminal plasma mucins, and the binding of mab
A46-B/BlO inhibited by serial dilutions of: A A Neutral carbo-
hydrates from seminal plasma mucins (SPL-N); 0 0 Sialy-
lated carbohydrates from seminal plasma mucins (SPL-A);
*O * Neutral carbohydrates from seminal plasma mucins after
hydrolytic removal of L-fucose residues.
In addition, a defined H type 1 oligosaccharide and the
simple disaccharide, N-acetyl-lactosamine, were also
included:
Fuccx(1-2)Galfl(1-3)GlcNAcB(1-3)Gal/3(1-4)Glc
(Lacto-N-fucopentaose I; H type 1 epitope; Led)
Gal,B(1-4)GlcNAc
(N-acetyl-lactosamine).
The results presented in Figure 3 show that the H type 2-
blood group active saccharide N4 contained in the fraction
of neutral carbohydrates (SPL-N) prepared from seminal
plasma mucins was the only potent inhibitor of A46-B/B10
antibody binding. A second L-fucose residue linked to the
subterminal N-acetyl-D-glucosamine (N8) rendered the mole-
cule non-competitive for the A46-B/B10 epitope. The same
was true for the H type 1 structure and the N-acetyl-
lactosamine disaccharide lacking L-fucose. Absorption experi-
ments performed with immobilized synthetic H type 1 and
type 2 oligosaccharides (Table IV) gave results in accordance
with the assumed H type 2 specificity, whereas the commer-
cial anti H mab was less specific in this respect. In conclu-
sion, the epitope structure recognized by antibody A46-B/
B10 comprises at least a trisaccharide sequence based on
the blood group H type 2 structure:
Fuca(1-2)Gal#(l-4)GlcNAc-
Discussion
One of the major advantages of the hybridoma technique
developed by Kohler and Milstein (1975) consists in its
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Figure 3 Binding inhibition experiments as in Figure 2 but with
purified glycoproteins and defined saccharides: A-A N4, puri-
fied from seminal plasma mucins: Fuca(1-2)Galf,(1-4)
GlcNAcf,(1-3)Gal,B(1-3)GalNAc-ol; +-+ N8, purified from
seminal plasma mucins: Fuca(1-2)Galfl(1-4)[Fuca(1-3)]
GlcNAc,B(1-3)Gal1B(l-3)GalNAc-ol; 0-0 Lacto-N-fucopentaose
I Fuca( -2)Galfl( -3)GlcNAc,B(1-3)Galfl(1-4)Glc; 0 0 N-
acetyl-lactosamine Gal,B(1-4)GlcNAc.
Table IV Absorption experiments with defined H type 1 and type 2
oligosaccharides coupled to an insoluble carrier
Synsorb HI Synsorb H2
Titre Titre
before after before after
Mab absorption absorption absorption absorption
A46-B/B10 1:64a 1:64 1:64 <1:2
(supernatant) 1:64 1:32b 1:64 < 1:2
Hc 1:16 1:2 1:16 < 1:2
(Chem-
biomed) 1:16 1:4 1:16 < 1:2
Titres were evaluated by haemagglutination with washed 0 erythro-
cytes; aTwo independent absorption experiments; bDue to the use of
washed Synsorb absorbent a slight dilution effect must occasionally
be reckoned with; cUndiluted reagent as supplied by the
manufacturer.
antigens. In pursuing this goal and using carcinoma cells or
cell lines as immunogens, several groups arrived at mabs
against blood group-related antigens (Ginsburg et al., 1984).
At first sight, this was surprising but there is now growing
awareness that these antigens are in fact among the most
common and most potent carcinoma associated antigens
(Hakomori, 1984; Ginsburg et al., 1984; Feizi, 1985;
Uhlenbruck, 1986). From the biochemical point of view,
different patterns of changes can be found depending on the
tissue of origin. Mammary and prostate carcinomas are
characterized by a loss of blood group isoantigens accompa-
nied by the accumulation of precursor substances (Vowden
et al., 1986a,b). On the contrary, distal colon and thyroid,
which in normal adult life lack blood group isoantigens, may
express these antigens in malignant state (Vowden et al.,
1986c). Another type of deviation consists in the synthesis of
modified (dimeric, sialylated, or more extensively fucosy-
lated) carbohydrate chains (Hakomori, 1984). The H type 2
n li r I
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antigen recognized by mab A46-B/B10 is a blood group
precursor and can therefore be considered a carcinoma-
associated antigen of tissues belonging to the first category.
It has been reported to accumulate in mammary carcinomas
(Vowden et al., 1986b), squamous cell carcinomas (Kimmel
et al., 1986), prostate carcinomas (Vowden et al., 1986a), and
precancerous oral epithelium (Dabelsteen et al., 1983). In
such studies the use of strictly specific and thoroughly tested
mabs is essential. A46-B/B10 seems to fulfil these criteria.
Only few others of the same or similar specificity have been
described (Young et al., 1981; Knowles et al., 1982; Fredman
et al., 1983; Feizi, 1985; Kimmel et al., 1986). Among these,
minor differences may exist. For instance, we cannot explain
to date the non-reactivity of mammary carcinomas other
than that from patients of blood group 0 with A46-B/B10 in
contrast to the results of Vowden et al. (1986b). A direct
comparison of the anti H type 2 mabs has not yet been
performed. Furthermore, the different amount of H antigen
expressed on subgroups (e.g. A2 vs. Al) has not yet been
taken into account by either study. On the other hand, some
preliminary data indicate that different methods of tissue
processing may bring about not merely preservation or loss
of an epitope but certain subtle changes in its pattern of
distribution. As compared to the H type 2 binding Ulex
europaeus I lectin, A46-B/B10 appears to be much more
specific, because this lectin cannot discriminate between H2
and Leb (Hindsgaul et al., 1985).
In principle, mab A46-B/B10 can be employed with cryo-
stat or paraffin sections. Although methacarn fixation is to
be preferred in the preparation of paraffin sections, formalin
fixed material can be used.
In studies on cells cultured in vitro, A46-B/B1O seems to
be a reagent able to identify certain epithelial lineages
independent of the blood group of the donor. The rules
governing carbohydrate antigen expression in vitro seem to
differ from those acting in vivo and await further explo-
ration. In recent experiments we were able, by using mab
A46-B/B10, to define an H type 2 positive subpopulation of
normal mammary epithelial cells cultured in vitro (see Figure
Id), which we consider to be stem cells (Karsten et al.,
1988). Available data suggest an onco-foetal mode of expres-
sion of the H type 2 antigen in mammary epithelial cells in
vitro.
A46-B/B1O is well suited in blood typing where it clearly
distinguishes between Al and A2 as well as between A1B
and A2B. Moreover, it seems to be able to reproducibly
define subtypes of B differing in their amount of H sub-
stance (Pilgrim & Karsten, 1987).
Very recently it has been shown by Rodeck et al. (1987)
that a mucin bearing X, Y and H type 2 determinants
(different from the mucin carrying the 19-9 epitope) is shed
by carcinoma cells. If this mucin can be found in patient
sera, this could open up yet another field of application for
anti H type 2 mabs such as A46-B/B10.
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